Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice

Acta Pharmacologica Sinica

Volumn 33, Issue 4, 2012, Pages 503-512

  Yan, Jun ^a   Hua, Fang ^a   Liu, Han Zhi ^a   Yang, Hong Zheng ^a   Hu, Zhuo Wei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

B16 F10 cells; CpG; immunotherapy; metastasis; Toll like receptor 2; Toll like receptor 9; Toll like receptor 2 neutralizing antibody; tumor microenvironment

Indexed keywords

ANTIMETASTATIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; INDOLEAMINE 2,3 DIOXYGENASE; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LUNG INFILTRATE; LUNG METASTASIS; LUNG PARENCHYMA; MACROPHAGE; MELANOMA B16; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; IMMUNOTHERAPY; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 9;

EID: 84859610132     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.193     Document Type: Article

References (33)

1. King J, Waxman J, Stauss H. Advances in tumour immunotherapy. QIM 2008; 101: 675-83.
2. Lasaro MO, Ertl HC. Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 2010; 22: 385-90.
3. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-74. (Pubitemid 46718401)
4. Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, et al. Immunotherapy of cancer: key findings and commentary on the Third Tegernsee Conference. The Oncologist 2010; 15: 112-8.
5. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat immunol 2010; 11: 373-84.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37. (Pubitemid 43053650)
7. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-94. (Pubitemid 46718403)
8. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007; 25: 825-6. (Pubitemid 47236890)
9. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 2006; 63: 449-68.
10. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218-24.
11. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006; 116: 2022-32.
12. Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PloS One 2009; 4: e6520.
13. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
14. Yan J, Wang ZY, Yang HZ, Liu HZ, Mi S, Lv XX, et al. Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNgamma/STAT1-mediated activation of autophagy. PloS One 2011; 6: e24705.
15. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-70. (Pubitemid 34293428)
16. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 2008; 86: 506-14.
17. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994; 55: 35-42.
18. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 2010; 28: 3548-57.
19. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev 2006; 6: 836-48. (Pubitemid 44631652)
20. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006; 6: 613-25. (Pubitemid 44140859)
21. Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2009; 379: 1027-32.
22. Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010; 10: 415.
23. Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PloS One 2009; 4: e8368.
24. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51. (Pubitemid 46020826)
25. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 2009; 183: 6303-12.
26. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR. Effective CpGimmunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res 2008; 14: 5484-93.
27. Netea MG, Van der Meer JW, Kullberg BJ. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol 2004; 12: 484-8. (Pubitemid 39370729)
28. + regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PloS One 2011; 6: e18833.
29. Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, et al. Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 2010; 15: 112-8.
30. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res 2008; 14: 5484-93.
31. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007; 67: 4346-52. (Pubitemid 46815083)
32. Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2010; 17: 67-76.
33. Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, Chen S, et al. Tolllike receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PloS One 2010; 5: e13027.